UEG Week 2025

IF 38.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Lancet Gastroenterology & Hepatology Pub Date : 2025-10-10 DOI:10.1016/s2468-1253(25)00321-8

Rob Brierley

{"title":"UEG Week 2025","authors":"Rob Brierley","doi":"10.1016/s2468-1253(25)00321-8","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>ABTECT 1 & 2</h2>Data from two randomised trials indicate that the microRNA upregulator obefazimod resulted in significantly higher rates of clinical remission at week 8 than did placebo in patients with moderately-to-severely active ulcerative colitis. Both trials, presented by Bruce E Sands (New York City, NY, USA), randomly assigned participants to receive obefazimod 25 mg, obefazimod 50 mg, or placebo. At week 8, in the ABTECT 1 trial, 38 (24%) of 160 patients receiving obefazimod 25 mg, 69 (22%) of 318</section></section><section><section><h2>TRIASSIC trial</h2>For en-bloc resection of large, non-pedunculated rectal lesions, endoscopic submucosal dissection (ESD) is non-inferior to transanal minimally invasive surgery (TAMIS) in terms of local recurrence at 12 months, according to data presented by Nik Dekkers (Leiden, the Netherlands). In the multicentre, randomised TRIASSIC trial, patients with non-pedunculated rectal lesions larger than 2 cm that were located at most 15 cm from the anal verge were randomly assigned to undergo either ESD (n=100) or</section></section><section><section><h2>WATERLAND trial</h2>Fluid resuscitation with lactated Ringer's solution in patients with acute pancreatitis did not improve key clinical outcomes compared with normal saline, according to the results of the WATERLAND trial. In this randomised controlled trial presented by Enrique de-Madaria (Alicante, Spain), patients with acute pancreatitis were randomly assigned to receive fluid resuscitation with either lactated Ringer's (n=399) or normal saline (n=393) for at least 48 h. Although there was evidence that</section></section><section><section><h2>The Mediterranean diet in irritable bowel syndrome</h2>The Mediterranean diet could be a new first-line dietary option for patients with irritable bowel syndrome (IBS), according to data presented by Imran Aziz (Sheffield, UK). In a randomised non-inferiority trial, individuals with IBS were randomly assigned to follow the Mediterranean diet (n=68) or traditional dietary advice (n=71) for 6 weeks. The primary endpoint was the proportion of participants achieving clinical response (defined as a 50-point or greater reduction in the IBS Symptom</section></section>","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"1 1","pages":""},"PeriodicalIF":38.6000,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2468-1253(25)00321-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

ABTECT 1 & 2

Data from two randomised trials indicate that the microRNA upregulator obefazimod resulted in significantly higher rates of clinical remission at week 8 than did placebo in patients with moderately-to-severely active ulcerative colitis. Both trials, presented by Bruce E Sands (New York City, NY, USA), randomly assigned participants to receive obefazimod 25 mg, obefazimod 50 mg, or placebo. At week 8, in the ABTECT 1 trial, 38 (24%) of 160 patients receiving obefazimod 25 mg, 69 (22%) of 318

TRIASSIC trial

For en-bloc resection of large, non-pedunculated rectal lesions, endoscopic submucosal dissection (ESD) is non-inferior to transanal minimally invasive surgery (TAMIS) in terms of local recurrence at 12 months, according to data presented by Nik Dekkers (Leiden, the Netherlands). In the multicentre, randomised TRIASSIC trial, patients with non-pedunculated rectal lesions larger than 2 cm that were located at most 15 cm from the anal verge were randomly assigned to undergo either ESD (n=100) or

WATERLAND trial

Fluid resuscitation with lactated Ringer's solution in patients with acute pancreatitis did not improve key clinical outcomes compared with normal saline, according to the results of the WATERLAND trial. In this randomised controlled trial presented by Enrique de-Madaria (Alicante, Spain), patients with acute pancreatitis were randomly assigned to receive fluid resuscitation with either lactated Ringer's (n=399) or normal saline (n=393) for at least 48 h. Although there was evidence that

The Mediterranean diet in irritable bowel syndrome

The Mediterranean diet could be a new first-line dietary option for patients with irritable bowel syndrome (IBS), according to data presented by Imran Aziz (Sheffield, UK). In a randomised non-inferiority trial, individuals with IBS were randomly assigned to follow the Mediterranean diet (n=68) or traditional dietary advice (n=71) for 6 weeks. The primary endpoint was the proportion of participants achieving clinical response (defined as a 50-point or greater reduction in the IBS Symptom

查看原文本刊更多论文

uec周2025

来自两项随机试验的数据表明，在中度至重度活动性溃疡性结肠炎患者中，microRNA上调剂obefazimod在第8周的临床缓解率显著高于安慰剂。这两项试验均由Bruce E Sands （New York City， NY， USA）提出，随机分配受试者接受奥贝法齐mod 25 mg、奥贝法齐mod 50 mg或安慰剂。第8周，在ABTECT 1试验中，160例患者中有38例（24%）接受了奥贝法莫25 mg， 318TRIASSIC试验中有69例（22%）。根据Nik Dekkers （Leiden, Netherlands）提供的数据，在12个月的局部复发率方面，内镜下粘膜下解剖（ESD）不低于经肛门微创手术（TAMIS）。在多中心随机TRIASSIC试验中，非带蒂直肠病变大于2 cm且位于肛门边缘最多15 cm的患者被随机分配进行ESD （n=100）或WATERLAND试验。根据WATERLAND试验的结果，与生理盐水相比，急性胰腺炎患者使用乳酸林格氏液进行液体复苏并没有改善关键临床结果。在这项由Enrique de-Madaria （Alicante, Spain）提出的随机对照试验中，急性胰腺炎患者被随机分配接受至少48小时的乳酸林格氏液（n=399）或生理盐水（n=393）液体复苏。尽管有证据表明，地中海饮食对肠易激综合征（IBS）患者可能是一种新的一线饮食选择。根据Imran Aziz （Sheffield， UK）提供的数据。在一项随机非劣效性试验中，肠易激综合征患者被随机分配到遵循地中海饮食（n=68）或传统饮食建议（n=71） 6周。主要终点是达到临床缓解的参与者比例（定义为IBS症状减少50分或以上）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lancet Gastroenterology & Hepatology Medicine-Hepatology

CiteScore

50.30

自引率

1.10%

发文量

期刊介绍： The Lancet Gastroenterology & Hepatology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The Lancet Gastroenterology & Hepatology publishes papers that reflect the rich variety of ongoing clinical research in these fields, especially in the areas of inflammatory bowel diseases, NAFLD and NASH, functional gastrointestinal disorders, digestive cancers, and viral hepatitis.